CN100389115C - 吡啶氧基甲基和苯并异唑氮杂二环衍生物 - Google Patents

吡啶氧基甲基和苯并异唑氮杂二环衍生物 Download PDF

Info

Publication number
CN100389115C
CN100389115C CNB2004800066516A CN200480006651A CN100389115C CN 100389115 C CN100389115 C CN 100389115C CN B2004800066516 A CNB2004800066516 A CN B2004800066516A CN 200480006651 A CN200480006651 A CN 200480006651A CN 100389115 C CN100389115 C CN 100389115C
Authority
CN
China
Prior art keywords
pyridin
ylmethyl
benzo
pyrido
isoxazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800066516A
Other languages
English (en)
Chinese (zh)
Other versions
CN1759116A (zh
Inventor
G·M·布莱特
M·A·布罗德尼
B·沃洛德奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1759116A publication Critical patent/CN1759116A/zh
Application granted granted Critical
Publication of CN100389115C publication Critical patent/CN100389115C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNB2004800066516A 2003-03-12 2004-02-23 吡啶氧基甲基和苯并异唑氮杂二环衍生物 Expired - Fee Related CN100389115C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45392503P 2003-03-12 2003-03-12
US60/453,925 2003-03-12

Publications (2)

Publication Number Publication Date
CN1759116A CN1759116A (zh) 2006-04-12
CN100389115C true CN100389115C (zh) 2008-05-21

Family

ID=32990837

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800066516A Expired - Fee Related CN100389115C (zh) 2003-03-12 2004-02-23 吡啶氧基甲基和苯并异唑氮杂二环衍生物

Country Status (30)

Country Link
US (1) US7345038B2 (cg-RX-API-DMAC10.html)
EP (1) EP1608648B1 (cg-RX-API-DMAC10.html)
JP (2) JP3910627B2 (cg-RX-API-DMAC10.html)
KR (2) KR100767854B1 (cg-RX-API-DMAC10.html)
CN (1) CN100389115C (cg-RX-API-DMAC10.html)
AP (1) AP2005003390A0 (cg-RX-API-DMAC10.html)
AR (1) AR043537A1 (cg-RX-API-DMAC10.html)
AU (2) AU2004220327B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0408248A (cg-RX-API-DMAC10.html)
CA (1) CA2518740C (cg-RX-API-DMAC10.html)
EA (1) EA009527B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP056011A (cg-RX-API-DMAC10.html)
GT (1) GT200400041A (cg-RX-API-DMAC10.html)
HR (1) HRP20050798A2 (cg-RX-API-DMAC10.html)
IL (1) IL170290A (cg-RX-API-DMAC10.html)
MA (1) MA27747A1 (cg-RX-API-DMAC10.html)
MX (1) MXPA05009660A (cg-RX-API-DMAC10.html)
NL (1) NL1025710C2 (cg-RX-API-DMAC10.html)
NO (1) NO20054095L (cg-RX-API-DMAC10.html)
OA (1) OA13038A (cg-RX-API-DMAC10.html)
PA (1) PA8597501A1 (cg-RX-API-DMAC10.html)
PE (1) PE20041057A1 (cg-RX-API-DMAC10.html)
PL (1) PL378749A1 (cg-RX-API-DMAC10.html)
RS (1) RS20050692A (cg-RX-API-DMAC10.html)
TN (1) TNSN05224A1 (cg-RX-API-DMAC10.html)
TW (1) TW200502234A (cg-RX-API-DMAC10.html)
UA (1) UA78437C2 (cg-RX-API-DMAC10.html)
UY (1) UY28225A1 (cg-RX-API-DMAC10.html)
WO (1) WO2004081007A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200506373B (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6994726B2 (en) * 2004-05-25 2006-02-07 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
ES2372694T3 (es) 2003-10-15 2012-01-25 OSI Pharmaceuticals, LLC Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
BRPI0507250A (pt) * 2004-01-29 2007-06-26 Pfizer Prod Inc combinações para tratar desordens do snc
MXPA06011423A (es) 2004-04-02 2007-01-23 Osi Pharm Inc Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico.
MY139689A (en) 2004-07-20 2009-10-30 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
CA2580042A1 (en) * 2004-09-10 2006-03-16 Pfizer Products Inc. Methods of treating cognitive disorders using pyridyloxymethyl and benzisoxazole azabicyclic derivatives
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
EP2250173A1 (en) * 2008-01-18 2010-11-17 OSI Pharmaceuticals, Inc. Imidazopyrazinol derivatives for the treatment of cancers
ES2396613T3 (es) * 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
EP2421837A1 (en) 2009-04-20 2012-02-29 OSI Pharmaceuticals, LLC Preparation of c-pyrazine-methylamines
WO2010129740A1 (en) * 2009-05-07 2010-11-11 Osi Pharmaceuticals, Inc. Use of osi-906 for treating adrenocortical carcinoma
JP2013540145A (ja) * 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2016115282A1 (en) * 2015-01-13 2016-07-21 Vanderbilt University Benzoisoxazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US20170038184A1 (en) 2015-08-06 2017-02-09 Charles E. Ankner Formulation delivery system
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
EP4429465A1 (en) 2021-11-10 2024-09-18 Symrise AG Compositions comprising trpm8 agonistic cooling agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1305477A (zh) * 1998-04-09 2001-07-25 辉瑞产品公司 氮杂双环5－ht1受体配体
CN1332740A (zh) * 1998-12-28 2002-01-23 辉瑞产品公司 用于抗抑郁疗法的5－ht1拮抗剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008148A1 (en) 1989-01-23 1990-07-26 Pfizer Inc. Bis-aza-bicyclic anxiolytic agents
US5167034A (en) * 1990-06-18 1992-11-24 International Business Machines Corporation Data integrity for compaction devices
US5157034A (en) 1991-02-27 1992-10-20 Pfizer Inc. Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
ES2096099T3 (es) 1991-09-25 1997-03-01 Pfizer Perhidro-1h-pirido(1,2,a)pirazinas 2-sustituidas neurolepticas.
WO1993025552A1 (en) 1992-06-16 1993-12-23 Pfizer Inc. Process and intermediates for bis-aza-bicyclic anxiolytic agents
WO1996010570A1 (en) 1994-09-30 1996-04-11 Pfizer Inc. NEUROLEPTIC 2,7-DISUBSTITUTED PERHYDRO-1H-PYRIDO[1,2-a]PYRAZINES
KR100589872B1 (ko) 1997-05-30 2006-06-15 뉴로서치 에이/에스 8-아자비사이클로(3,2,1)옥트-2-엔 유도체 및 이의 제조방법
PT1114028E (pt) 1998-08-26 2007-02-28 Aventis Pharma Ltd Aza-biciclos moduladores da inibição da adesão celular
CZ2001959A3 (cs) 1998-09-18 2001-12-12 Basf Aktiengesellschaft 4-Aminopyrrolopyrimidiny jako inhibitory kinasy
NZ510588A (en) 1998-09-18 2003-08-29 Abbott Gmbh & Co Pyrrolopyrimidines as protein kinase inhibitors
TR200102817T2 (tr) 1999-03-12 2002-05-21 Boehringer Ingelheim Pharmaceuticals, Inc. Antiinflamatuar ajanlar olarak faydalı bileşikler
EP1177792A3 (en) * 2000-07-27 2002-10-23 Pfizer Products Inc. Dopamine D4 Ligands for the treatment of novelty-seeking disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1305477A (zh) * 1998-04-09 2001-07-25 辉瑞产品公司 氮杂双环5－ht1受体配体
CN1332740A (zh) * 1998-12-28 2002-01-23 辉瑞产品公司 用于抗抑郁疗法的5－ht1拮抗剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
The Practise of Medicinal Chemistry. Wermuth.C.G,210-215. 1996
The Practise of Medicinal Chemistry. Wermuth.C.G,210-215. 1996 *

Also Published As

Publication number Publication date
CN1759116A (zh) 2006-04-12
MXPA05009660A (es) 2005-10-20
AU2010203303A1 (en) 2010-08-12
KR20070074667A (ko) 2007-07-12
KR100767854B1 (ko) 2007-10-17
NL1025710A1 (nl) 2004-09-14
UA78437C2 (en) 2007-03-15
HK1085725A1 (zh) 2006-09-01
PE20041057A1 (es) 2005-01-22
CA2518740C (en) 2011-01-11
EA200501148A1 (ru) 2006-04-28
JP2006519830A (ja) 2006-08-31
PL378749A1 (pl) 2006-05-15
CA2518740A1 (en) 2004-09-23
TNSN05224A1 (fr) 2007-06-11
NL1025710C2 (nl) 2005-10-10
RS20050692A (sr) 2007-11-15
EA009527B1 (ru) 2008-02-28
UY28225A1 (es) 2004-11-08
NO20054095L (no) 2005-09-26
EP1608648B1 (en) 2012-07-18
HRP20050798A2 (en) 2006-02-28
BRPI0408248A (pt) 2006-03-01
JP3910627B2 (ja) 2007-04-25
ZA200506373B (en) 2006-10-25
JP2007051155A (ja) 2007-03-01
WO2004081007A1 (en) 2004-09-23
PA8597501A1 (es) 2005-05-24
TW200502234A (en) 2005-01-16
MA27747A1 (fr) 2006-02-01
AP2005003390A0 (en) 2005-09-30
AU2004220327B2 (en) 2010-06-24
AR043537A1 (es) 2005-08-03
KR20050113221A (ko) 2005-12-01
NO20054095D0 (no) 2005-09-02
US7345038B2 (en) 2008-03-18
ECSP056011A (es) 2006-01-27
US20050026922A1 (en) 2005-02-03
EP1608648A1 (en) 2005-12-28
AU2004220327A1 (en) 2004-09-23
GT200400041A (es) 2005-03-23
OA13038A (en) 2006-11-10
IL170290A (en) 2011-02-28

Similar Documents

Publication Publication Date Title
TWI378101B (en) Pyridine derivatives and their use in the treatment of psychotic disorders
AU2017200886B2 (en) PDE9 inhibitors with imidazo triazinone backbone
CA2956129C (en) New spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
JP6609631B2 (ja) 縮合環ヘテロアリール化合物及びｔｒｋ抑制剤としての用途
AU2010203303A1 (en) Pyridyloxymethyl and benzisoxazole azabicyclic derivatives
EA039783B1 (ru) ПРОИЗВОДНЫЕ ТИРОЗИНАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
AU2015335703A1 (en) Carbazole derivatives
WO2011076744A1 (en) Disubstituted heteroaryl-fused pyridines
HK1254348A1 (zh) 毒蕈碱性m2受体的正性变构调节剂
JPWO2006137350A1 (ja) 新規なフロピリジン誘導体、それを含有する医薬組成物およびそれらの用途
EP3057963B1 (en) Piperazine derivatives and the use thereof as medicament
TW201602116A (zh) 作為β－分泌酶抑制劑之橋接二環胺基噻嗪二氧化物化合物及其使用方法
EP4229052A1 (en) Novel compounds
CN119948015A (zh) 新型磺胺及其作为神经保护剂和/或神经修复剂的用途
JP2008521771A (ja) 改良された抗精神病活性および抗不安症活性を有するイソキサゾリン−インドール誘導体
HK1085725B (en) Pyridyloxymethyl and benzisoxazole azabicyclic derivatives
CA3000063C (en) Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
WO2025133191A1 (en) Novel sulfonamides or sulfones and their use as neuroprotective and/or neurorestorative agents
CN117466893A (zh) 吡啶并环庚烷类衍生物及其制备方法和用途
CA3000063A1 (en) Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1085725

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1085725

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080521

Termination date: 20120223